
Your Feed
Understanding Prolonged Low Blood Counts After CAR-T Therapy |Zachary Avigan, MD | ASCO YIA
Using Evolving Biomarkers to ID High-Risk SMM-a Dynamic Model | Theresia Akhlaghi, MD| EHA25
How are donors selected for an allo transplant?
If I am not eligible for transplant what treatment options should I consider? How effective are these treatments compared to transplant?
What is the process of donating stem cells for allo, is there a difference between the two methods
Is it possible to have no response to transplant?
Disparities in Accessing CAR-T and Bispecific Antibody Therapies | Craig Cole, MD | EHA 2025
What t-cell redirecting therapies have beed FDA approved? What are there indications?
What is the role of sedation for bone marrow biopsies?
EHA 2025 Myeloma Overview | Claudio Cerchione, MD | EHA 2025 #myeloma
IRAKLIA- On-Body Isatuximab Matches IV Delivery = More Convenient Care| Claudio Cerchione,MD | EHA25
Socioeconomic Inequalities & Quality of Life in Myeloma | Francesco Sparano, MSc | #EHA2025
What ways are being explored to revitalize exhausted t-cells?